The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies

DOI record: { "DOI": "10.1007/s43441-024-00633-6", "ISSN": [ "2168-4790", "2168-4804" ], "URL": "http://dx.doi.org/10.1007/s43441-024-00633-6", "alternative-id": [ "633" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "6 September 2023" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "9 February 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "29 April 2024" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Competing Interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare no competing interests." }, { "group": { "label": "Ethical Approval", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "Not applicable." } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-8157-3040", "affiliation": [], "authenticated-orcid": false, "family": "Song", "given": "Zhi-Hui", "sequence": "first" }, { "affiliation": [], "family": "Huang", "given": "Qiao-Ming", "sequence": "additional" }, { "affiliation": [], "family": "Xu", "given": "Shan-Shan", "sequence": "additional" }, { "affiliation": [], "family": "Zhou", "given": "Jian-Bo", "sequence": "additional" }, { "affiliation": [], "family": "Zhang", "given": "Chao", "sequence": "additional" } ], "container-title": "Therapeutic Innovation & Regulatory Science", "container-title-short": "Ther Innov Regul Sci", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 4, 29 ] ], "date-time": "2024-04-29T14:02:38Z", "timestamp": 1714399358000 }, "deposited": { "date-parts": [ [ 2024, 4, 29 ] ], "date-time": "2024-04-29T14:19:03Z", "timestamp": 1714400343000 }, "funder": [ { "DOI": "10.13039/501100001809", "award": [ "NO 82070851" ], "doi-asserted-by": "publisher", "name": "National Natural Science Foundation of China" } ], "indexed": { "date-parts": [ [ 2024, 4, 30 ] ], "date-time": "2024-04-30T00:29:07Z", "timestamp": 1714436947425 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 4, 29 ] ] }, "language": "en", "license": [ { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 4, 29 ] ], "date-time": "2024-04-29T00:00:00Z", "timestamp": 1714348800000 } }, { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 4, 29 ] ], "date-time": "2024-04-29T00:00:00Z", "timestamp": 1714348800000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s43441-024-00633-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s43441-024-00633-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s43441-024-00633-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2024, 4, 29 ] ] }, "published-online": { "date-parts": [ [ 2024, 4, 29 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "633_CR1", "unstructured": "W.H.O. Coronavirus disease (COVID-19) pandemic. 11 November 2022; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019." }, { "key": "633_CR2", "unstructured": "Federation, I.D. The IDF Diabetes Atlas 10th edition 2021. 2021 6 December 2021; Available from: https://diabetesatlas.org/." }, { "DOI": "10.1111/dom.14105", "author": "J Wu", "doi-asserted-by": "publisher", "first-page": "1907", "journal-title": "Diabetes Obes Metab", "key": "633_CR3", "unstructured": "Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. Diabetes Obes Metab. 2020;22:1907–14.", "volume": "22", "year": "2020" }, { "DOI": "10.1001/jama.2020.2648", "author": "Z Wu", "doi-asserted-by": "publisher", "first-page": "1239", "journal-title": "JAMA", "key": "633_CR4", "unstructured": "Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239.", "volume": "323", "year": "2020" }, { "DOI": "10.1016/S2213-8587(21)00315-6", "author": "T Burki", "doi-asserted-by": "publisher", "first-page": "23", "journal-title": "Lancet Diabetes Endocrinol", "key": "633_CR5", "unstructured": "Burki T. COVID-19 and diabetes in Africa: a lethal combination. Lancet Diabetes Endocrinol. 2022;10:23.", "volume": "10", "year": "2022" }, { "DOI": "10.1016/j.jdiacomp.2020.107723", "author": "N Katsiki", "doi-asserted-by": "publisher", "first-page": "107723", "journal-title": "J Diabetes Complications", "key": "633_CR6", "unstructured": "Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era? J Diabetes Complications. 2020;34:107723.", "volume": "34", "year": "2020" }, { "DOI": "10.1007/s13300-020-00858-2", "author": "DM Williams", "doi-asserted-by": "publisher", "first-page": "1915", "journal-title": "Diabetes Ther", "key": "633_CR7", "unstructured": "Williams DM, Nawaz A, Evans M. Diabetes and novel coronavirus infection: implications for treatment. Diabetes Ther. 2020;11:1915–24.", "volume": "11", "year": "2020" }, { "DOI": "10.2337/db21-0385", "author": "JE Nyland", "doi-asserted-by": "publisher", "first-page": "2903", "journal-title": "Diabetes", "key": "633_CR8", "unstructured": "Nyland JE, Raja-Khan NT, Bettermann K, Haouzi PA, Leslie DL, Kraschnewski JL, et al. Diabetes, drug treatment, and mortality in COVID-19: a multinational retrospective cohort study. Diabetes. 2021;70:2903–16.", "volume": "70", "year": "2021" }, { "DOI": "10.1007/s00592-020-01539-z", "author": "SB Solerte", "doi-asserted-by": "publisher", "first-page": "779", "journal-title": "Acta Diabetol", "key": "633_CR9", "unstructured": "Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57:779–83.", "volume": "57", "year": "2020" }, { "DOI": "10.3390/molecules25092076", "author": "C Ciavarella", "doi-asserted-by": "publisher", "first-page": "2076", "journal-title": "Molecules", "key": "633_CR10", "unstructured": "Ciavarella C, Motta I, Valente S, Pasquinelli G. Pharmacological (or Synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease. Molecules. 2020;25:2076.", "volume": "25", "year": "2020" }, { "DOI": "10.1007/s40200-021-00777-4", "author": "TI Hariyanto", "doi-asserted-by": "publisher", "first-page": "543", "journal-title": "J Diabetes Metab Disord", "key": "633_CR11", "unstructured": "Hariyanto TI, Kurniawan A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord. 2021;20:543–50.", "volume": "20", "year": "2021" }, { "DOI": "10.1016/j.arcmed.2021.08.002", "author": "T Han", "doi-asserted-by": "publisher", "first-page": "186", "journal-title": "Arch Med Res", "key": "633_CR12", "unstructured": "Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, et al. Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: a systematic review and meta-analysis. Arch Med Res. 2022;53:186–95.", "volume": "53", "year": "2022" }, { "DOI": "10.1016/j.diabres.2021.109031", "author": "TI Hariyanto", "doi-asserted-by": "publisher", "first-page": "109031", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR13", "unstructured": "Hariyanto TI, Intan D, Hananto JE, Putri C, Kurniawan A. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021;179:109031.", "volume": "179", "year": "2021" }, { "key": "633_CR14", "unstructured": "World Health O. Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999." }, { "DOI": "10.1371/journal.pmed.1000097", "author": "D Moher", "doi-asserted-by": "publisher", "first-page": "e1000097", "journal-title": "PLoS Med", "key": "633_CR15", "unstructured": "Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.", "volume": "6", "year": "2009" }, { "DOI": "10.1007/s10654-010-9491-z", "author": "A Stang", "doi-asserted-by": "publisher", "first-page": "603", "journal-title": "Eur J Epidemiol", "key": "633_CR16", "unstructured": "Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.", "volume": "25", "year": "2010" }, { "key": "633_CR17", "unstructured": "Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Cochrane2022." }, { "DOI": "10.3389/fendo.2021.794382", "author": "R Abuhasira", "doi-asserted-by": "publisher", "journal-title": "Front Endocrinol", "key": "633_CR18", "unstructured": "Abuhasira R, Ayalon-Dangur I, Zaslavsky N, Koren R, Keller M, Dicker D, et al. A randomized clinical trial of Linagliptin vs. standard of care in patients hospitalized with diabetes and COVID-19. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.794382.", "year": "2021" }, { "DOI": "10.2337/dc20-1543", "author": "S Agarwal", "doi-asserted-by": "publisher", "first-page": "2339", "journal-title": "Diabetes Care", "key": "633_CR19", "unstructured": "Agarwal S, Schechter C, Southern W, Crandall JP, Tomer Y. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019. Diabetes Care. 2020;43:2339–44.", "volume": "43", "year": "2020" }, { "DOI": "10.15537/smj.2020.10.25419", "author": "AA Al Hayek", "doi-asserted-by": "publisher", "first-page": "1090", "journal-title": "Saudi Med J", "key": "633_CR20", "unstructured": "Al Hayek AA, Robert AA, Bin Matar A, Algarni A, Alkubedan H, Alharbi T, et al. Risk factors for hospital admission among COVID-19 patients with diabetes a study from Saudi Arabia. Saudi Med J. 2020;41:1090–7.", "volume": "41", "year": "2020" }, { "DOI": "10.1007/s13300-021-01110-1", "author": "KS Boye", "doi-asserted-by": "publisher", "first-page": "2223", "journal-title": "Diabetes Ther", "key": "633_CR21", "unstructured": "Boye KS, Tokar Erdemir E, Zimmerman N, Reddy A, Benneyworth BD, Dabora MC, et al. Risk factors associated with COVID-19 hospitalization and mortality: a large claims-based analysis among people with type 2 diabetes mellitus in the United States. Diabetes Ther. 2021;12:2223–9.", "volume": "12", "year": "2021" }, { "DOI": "10.1016/S2666-7568(20)30033-7", "author": "CT Bramante", "doi-asserted-by": "publisher", "first-page": "e34", "journal-title": "Lancet Healthy Longev", "key": "633_CR22", "unstructured": "Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2:e34-41.", "volume": "2", "year": "2021" }, { "DOI": "10.1007/s00125-020-05180-x", "author": "B Cariou", "doi-asserted-by": "publisher", "first-page": "1500", "journal-title": "Diabetologia", "key": "633_CR23", "unstructured": "Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500–15.", "volume": "63", "year": "2020" }, { "author": "A Cernigliaro", "first-page": "315", "journal-title": "Epidemiol Prev", "key": "633_CR24", "unstructured": "Cernigliaro A, Allotta AV. Scondotto S [Can diabetes and its related hypoglycemic drug treatment be considered risk factors for health outcomes in COVID-19 patients? The results of a study in the population residing in Sicily Region (Southern Italy)]. Epidemiol Prev. 2020;44:315–22.", "volume": "44", "year": "2020" }, { "DOI": "10.2337/dc20-0660", "author": "Y Chen", "doi-asserted-by": "publisher", "first-page": "1399", "journal-title": "Diabetes Care", "key": "633_CR25", "unstructured": "Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43:1399–407.", "volume": "43", "year": "2020" }, { "DOI": "10.1016/j.cmet.2020.08.013", "author": "X Cheng", "doi-asserted-by": "publisher", "first-page": "537", "journal-title": "Cell Metab", "key": "633_CR26", "unstructured": "Cheng X, Liu Y-M, Li H, Zhang X, Lei F, Qin J-J, et al. Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;32:537-47.e3.", "volume": "32", "year": "2020" }, { "DOI": "10.1016/j.lfs.2021.119371", "author": "X Cheng", "doi-asserted-by": "publisher", "first-page": "119371", "journal-title": "Life Sci", "key": "633_CR27", "unstructured": "Cheng X, Xin S, Chen Y, Li L, Chen W, Li W, et al. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study. Life Sci. 2021;275:119371.", "volume": "275", "year": "2021" }, { "DOI": "10.1093/ehjcvp/pvaa098", "author": "R Dalan", "doi-asserted-by": "publisher", "first-page": "e48", "journal-title": "Eur Heart J Cardiovasc Pharmacother", "key": "633_CR28", "unstructured": "Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC, Chan Y-H, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2020;7:e48-51.", "volume": "7", "year": "2020" }, { "DOI": "10.1016/j.diabres.2021.108925", "author": "JA Dave", "doi-asserted-by": "publisher", "first-page": "108925", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR29", "unstructured": "Dave JA, Tamuhla T, Tiffin N, Levitt NS, Ross IL, Toet W, et al. Risk factors for COVID-19 hospitalisation and death in people living with diabetes: a virtual cohort study from the Western Cape Province, South Africa. Diabetes Res Clin Pract. 2021;177:108925.", "volume": "177", "year": "2021" }, { "DOI": "10.1016/j.diabet.2020.10.006", "author": "JY Do", "doi-asserted-by": "publisher", "first-page": "101208", "journal-title": "Diabetes Metab", "key": "633_CR30", "unstructured": "Do JY, Kim SW, Park JW, Cho KH, Kang SH. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Diabetes Metab. 2021;47:101208.", "volume": "47", "year": "2021" }, { "DOI": "10.1007/s13300-021-01133-8", "author": "R Emral", "doi-asserted-by": "publisher", "first-page": "2857", "journal-title": "Diabetes Ther", "key": "633_CR31", "unstructured": "Emral R, Haymana C, Demirci I, Tasci I, Sahin M, Cakal E, et al. Lower COVID-19 mortality in patients with type 2 diabetes mellitus taking dipeptidyl peptidase-4 inhibitors: results from a Turkish nationwide study. Diabetes Ther. 2021;12:2857–70.", "volume": "12", "year": "2021" }, { "DOI": "10.1111/dom.14097", "author": "GP Fadini", "doi-asserted-by": "publisher", "first-page": "1946", "journal-title": "Diabetes Obes Metab", "key": "633_CR32", "unstructured": "Fadini GP, Morieri ML, Longato E, Bonora BM, Pinelli S, Selmin E, et al. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study. Diabetes Obes Metab. 2020;22:1946–50.", "volume": "22", "year": "2020" }, { "DOI": "10.1111/cts.12897", "author": "Y Gao", "doi-asserted-by": "publisher", "first-page": "1055", "journal-title": "Clin Transl Sci", "key": "633_CR33", "unstructured": "Gao Y, Liu T, Zhong W, Liu R, Zhou H, Huang W, et al. Risk of Metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report. Clin Transl Sci. 2020;13:1055–9.", "volume": "13", "year": "2020" }, { "DOI": "10.1016/j.dsx.2021.02.022", "author": "R Ghany", "doi-asserted-by": "publisher", "first-page": "513", "journal-title": "Diabetes Metab Syndr", "key": "633_CR34", "unstructured": "Ghany R, Palacio A, Dawkins E, Chen G, McCarter D, Forbes E, et al. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes Metab Syndr. 2021;15:513–8.", "volume": "15", "year": "2021" }, { "DOI": "10.1016/j.diabres.2021.109021", "author": "CB Giorda", "doi-asserted-by": "publisher", "first-page": "109021", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR35", "unstructured": "Giorda CB, Picariello R, Tartaglino B, Nada E, Doglio M, Romeo F, et al. From swab testing to health outcomes within the T2DM population: Impact of diabetes background on COVID19 progression. Diabetes Res Clin Pract. 2021;180:109021.", "volume": "180", "year": "2021" }, { "DOI": "10.1038/s41598-021-04511-1", "author": "R Guardado-Mendoza", "doi-asserted-by": "publisher", "journal-title": "Sci Rep", "key": "633_CR36", "unstructured": "Guardado-Mendoza R, Garcia-Magaña MA, Martínez-Navarro LJ, Macías-Cervantes HE, Aguilar-Guerrero R, Suárez-Pérez EL, et al. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. Sci Rep. 2022. https://doi.org/10.1038/s41598-021-04511-1.", "year": "2022" }, { "DOI": "10.1111/dom.14329", "author": "SB Israelsen", "doi-asserted-by": "publisher", "first-page": "1397", "journal-title": "Diabetes Obes Metab", "key": "633_CR37", "unstructured": "Israelsen SB, Pottegård A, Sandholdt H, Madsbad S, Thomsen RW, Benfield T. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes Obes Metab. 2021;23:1397–401.", "volume": "23", "year": "2021" }, { "DOI": "10.1016/j.diabres.2020.108619", "author": "N Jiang", "doi-asserted-by": "publisher", "first-page": "108619", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR38", "unstructured": "Jiang N, Chen Z, Liu L, Yin X, Yang H, Tan X, et al. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract. 2021;173:108619.", "volume": "173", "year": "2021" }, { "DOI": "10.2337/dc21-0065", "author": "AR Kahkoska", "doi-asserted-by": "publisher", "first-page": "1564", "journal-title": "Diabetes Care", "key": "633_CR39", "unstructured": "Kahkoska AR, Abrahamsen TJ, Alexander GC, Bennett TD, Chute CG, Haendel MA, et al. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care. 2021;44:1564–72.", "volume": "44", "year": "2021" }, { "DOI": "10.1016/j.jcjd.2020.10.014", "author": "S Khalili", "doi-asserted-by": "publisher", "first-page": "524", "journal-title": "Can J Diabetes", "key": "633_CR40", "unstructured": "Khalili S, Moradi O, Kharazmi AB, Raoufi M, Sistanizad M, Shariat M. Comparison of mortality rate and severity of pulmonary involvement in coronavirus disease-2019 adult patients with and without type 2 diabetes: a cohort study. Can J Diabetes. 2021;45:524–30.", "volume": "45", "year": "2021" }, { "DOI": "10.1016/S2213-8587(21)00050-4", "author": "K Khunti", "doi-asserted-by": "publisher", "first-page": "293", "journal-title": "Lancet Diabetes Endocrinol", "key": "633_CR41", "unstructured": "Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9:293–303.", "volume": "9", "year": "2021" }, { "DOI": "10.4093/dmj.2020.0146", "author": "MK Kim", "doi-asserted-by": "publisher", "first-page": "602", "journal-title": "South Korea Diabetes Metab J", "key": "633_CR42", "unstructured": "Kim MK, Jeon J-H, Kim S-W, Moon JS, Cho NH, Han E, et al. The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu. South Korea Diabetes Metab J. 2020;44:602.", "volume": "44", "year": "2020" }, { "DOI": "10.1016/S2213-8587(21)00180-7", "author": "MN Kosiborod", "doi-asserted-by": "publisher", "first-page": "586", "journal-title": "Lancet Diabetes Endocrinol", "key": "633_CR43", "unstructured": "Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:586–94.", "volume": "9", "year": "2021" }, { "DOI": "10.1016/j.eprac.2021.05.011", "author": "MM Kristan", "doi-asserted-by": "publisher", "first-page": "842", "journal-title": "Endocrine Practice.", "key": "633_CR44", "unstructured": "Kristan MM, Kim YK, Nelson T, Moxley MC, Yip TC-F, Munir K, et al. Predictors of severe COVID-19 in patients with diabetes: a multicenter review. Endocrine Practice. 2021;27:842–9.", "volume": "27", "year": "2021" }, { "DOI": "10.1016/j.diabet.2020.101216", "author": "J-D Lalau", "doi-asserted-by": "publisher", "first-page": "101216", "journal-title": "Diabetes Metab", "key": "633_CR45", "unstructured": "Lalau J-D, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M, et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 2021;47:101216.", "volume": "47", "year": "2021" }, { "DOI": "10.1016/j.jamda.2020.10.031", "author": "MA Lally", "doi-asserted-by": "publisher", "first-page": "193", "journal-title": "J Am Med Dir Assoc", "key": "633_CR46", "unstructured": "Lally MA, Tsoukas P, Halladay CW, O’Neill E, Gravenstein S, Rudolph JL. Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2. J Am Med Dir Assoc. 2021;22:193–8.", "volume": "22", "year": "2021" }, { "DOI": "10.21203/rs.3.rs-287308/v1", "doi-asserted-by": "crossref", "key": "633_CR47", "unstructured": "Li J, Wei Q, McCowen K, Xiong W, Liu J, Jiang W, et al. (2021) Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus. research square platform LLC." }, { "DOI": "10.1136/bmjopen-2021-052310", "author": "AOY Luk", "doi-asserted-by": "publisher", "first-page": "e052310", "journal-title": "BMJ Open.", "key": "633_CR48", "unstructured": "Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW-S, Ma RCW, et al. Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. BMJ Open. 2021;11:e052310.", "volume": "11", "year": "2021" }, { "DOI": "10.4269/ajtmh.20-0375", "author": "P Luo", "doi-asserted-by": "publisher", "first-page": "69", "journal-title": "Am J Trop Med Hyg", "key": "633_CR49", "unstructured": "Luo P, Qiu L, Liu Y, Liu X-l, Zheng J-l, Xue H-y, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg. 2020;103:69–72.", "volume": "103", "year": "2020" }, { "DOI": "10.4239/wjd.v12.i10.1789", "author": "S-K Luo", "doi-asserted-by": "publisher", "first-page": "1789", "journal-title": "World J Diabetes", "key": "633_CR50", "unstructured": "Luo S-K, Hu W-H, Lu Z-J, Li C, Fan Y-M, Chen Q-J, et al. Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: a retrospective study. World J Diabetes. 2021;12:1789–808.", "volume": "12", "year": "2021" }, { "DOI": "10.1038/s41598-022-09639-2", "author": "Z Ma", "doi-asserted-by": "publisher", "journal-title": "Sci Rep", "key": "633_CR51", "unstructured": "Ma Z, Patel N, Vemparala P, Krishnamurthy M. Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus. Sci Rep. 2022. https://doi.org/10.1038/s41598-022-09639-2.", "year": "2022" }, { "author": "A Mansour", "first-page": "1533", "journal-title": "EXCLI J", "key": "633_CR52", "unstructured": "Mansour A, Sajjadi-Jazi SM, Kasaeian A, Khosravi B, Sorouri M, Azizi F, et al. Clinical characteristics and outcomes of diabetics hospitalized for covid-19 infection: a single-centered, retrospective, observational study. EXCLI J. 2020;19:1533–43.", "volume": "19", "year": "2020" }, { "DOI": "10.2337/dc20-1824", "author": "Y Noh", "doi-asserted-by": "publisher", "first-page": "E64", "journal-title": "Diabetes Care", "key": "633_CR53", "unstructured": "Noh Y, Oh I-S, Jeong HE, Filion KB, Yu OHY, Shin J-Y. Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes. Diabetes Care. 2021;44:E64-6.", "volume": "44", "year": "2021" }, { "DOI": "10.1007/s00592-020-01666-7", "author": "TK Oh", "doi-asserted-by": "publisher", "first-page": "771", "journal-title": "Acta Diabetol", "key": "633_CR54", "unstructured": "Oh TK, Song I-A. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Acta Diabetol. 2021;58:771–8.", "volume": "58", "year": "2021" }, { "DOI": "10.1186/s12916-020-01832-2", "author": "LM Perez-Belmonte", "doi-asserted-by": "publisher", "journal-title": "Bmc Med", "key": "633_CR55", "unstructured": "Perez-Belmonte LM, Torres-Pena JD, Lopez-Carmona MD, Ayala-Gutierrez MM, Fuentes-Jimenez F, Huerta LJ, et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. Bmc Med. 2020. https://doi.org/10.1186/s12916-020-01832-2.", "year": "2020" }, { "DOI": "10.1093/gerona/glab124", "author": "JM Ramos-Rincón", "doi-asserted-by": "publisher", "first-page": "e102", "journal-title": "J Gerontol A Biol Sci Med Sci", "key": "633_CR56", "unstructured": "Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic therapy and mortality in very old patients with diabetes hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021;76:e102-9.", "volume": "76", "year": "2021" }, { "DOI": "10.1111/dom.14324", "author": "R Roussel", "doi-asserted-by": "publisher", "first-page": "1162", "journal-title": "Diabetes Obes Metab", "key": "633_CR57", "unstructured": "Roussel R, Darmon P, Pichelin M, Goronflot T, Abouleka Y, Ait Bachir L, et al. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study. Diabetes Obes Metab. 2021;23:1162–72.", "volume": "23", "year": "2021" }, { "DOI": "10.1016/j.diabres.2021.108753", "author": "I Satman", "doi-asserted-by": "publisher", "first-page": "108753", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR58", "unstructured": "Satman I, Demirci I, Haymana C, Tasci I, Salman S, Ata N, et al. Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul. Diabetes Res Clin Pract. 2021;174:108753.", "volume": "174", "year": "2021" }, { "DOI": "10.1007/s11845-021-02823-9", "author": "ES Saygili", "doi-asserted-by": "publisher", "first-page": "569", "journal-title": "Ir J Med Sci", "key": "633_CR59", "unstructured": "Saygili ES, Karakiliç E, Mert E, Şener A, Mirci A. Preadmission usage of metformin and mortality in COVID-19 patients including the post-discharge period. Ir J Med Sci. 2021;191:569–75.", "volume": "191", "year": "2021" }, { "DOI": "10.2337/dc20-1521", "author": "SB Solerte", "doi-asserted-by": "publisher", "first-page": "2999", "journal-title": "Observ Study Diabetes Care", "key": "633_CR60", "unstructured": "Solerte SB, D’Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective. Observ Study Diabetes Care. 2020;43:2999–3006.", "volume": "43", "year": "2020" }, { "DOI": "10.1111/dom.14256", "author": "H Sourij", "doi-asserted-by": "publisher", "first-page": "589", "journal-title": "Diabetes Obes Metab", "key": "633_CR61", "unstructured": "Sourij H, Aziz F, Bräuer A, Ciardi C, Clodi M, Fasching P, et al. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes Metab. 2021;23:589–98.", "volume": "23", "year": "2021" }, { "DOI": "10.1186/s13098-021-00695-8", "author": "RE Tamura", "doi-asserted-by": "publisher", "journal-title": "Diabetol Metab Syndr", "key": "633_CR62", "unstructured": "Tamura RE, Said SM, de Freitas LM, Rubio IGS. Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies. Diabetol Metab Syndr. 2021. https://doi.org/10.1186/s13098-021-00695-8.", "year": "2021" }, { "DOI": "10.1007/s11239-022-02631-7", "author": "A Usman", "doi-asserted-by": "publisher", "first-page": "363", "journal-title": "J Thromb Thrombolysis", "key": "633_CR63", "unstructured": "Usman A, Bliden KP, Cho A, Walia N, Jerjian C, Singh A, et al. Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. J Thromb Thrombolysis. 2022;53:363–71.", "volume": "53", "year": "2022" }, { "DOI": "10.2337/dc21-1351", "author": "PL Wander", "doi-asserted-by": "publisher", "first-page": "2708", "journal-title": "Diabetes Care", "key": "633_CR64", "unstructured": "Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC, et al. Prior glucose-lowering medication use and 30-day outcomes among 64,892 veterans with diabetes and COVID-19. Diabetes Care. 2021;44:2708–13.", "volume": "44", "year": "2021" }, { "DOI": "10.1210/clinem/dgab067", "author": "J Wang", "doi-asserted-by": "publisher", "first-page": "1255", "journal-title": "J Clin Endocrinol Metab", "key": "633_CR65", "unstructured": "Wang J, Cooper JM, Gokhale K, Acosta-Mena D, Dhalla S, Byne N, et al. Association of metformin with susceptibility to COVID-19 in people with type 2 diabetes. J Clin Endocrinol Metab. 2021;106:1255–68.", "volume": "106", "year": "2021" }, { "DOI": "10.1007/s00125-020-05351-w", "author": "M Wargny", "doi-asserted-by": "publisher", "first-page": "778", "journal-title": "Diabetologia", "key": "633_CR66", "unstructured": "Wargny M, Potier L, Gourdy P, Pichelin M, Amadou C, Benhamou P-Y, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia. 2021;64:778–94.", "volume": "64", "year": "2021" }, { "DOI": "10.1016/j.diabet.2021.101307", "author": "CKH Wong", "doi-asserted-by": "publisher", "first-page": "101307", "journal-title": "Diabetes Metab", "key": "633_CR67", "unstructured": "Wong CKH, Lui DTW, Lui AYC, Kwok ACY, Low MCH, Lau KTK, et al. Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: propensity score analysis of a territory-wide cohort in Hong Kong. Diabetes Metab. 2022;48:101307.", "volume": "48", "year": "2022" }, { "DOI": "10.1002/cpt.2047", "author": "H Yan", "doi-asserted-by": "publisher", "first-page": "1185", "journal-title": "Clin Pharmacol Ther", "key": "633_CR68", "unstructured": "Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, et al. Role of Drugs used for chronic disease management on susceptibility and severity of COVID-19: a large case-control study. Clin Pharmacol Ther. 2020;108:1185–94.", "volume": "108", "year": "2020" }, { "DOI": "10.1016/j.cmet.2020.11.014", "author": "B Yu", "doi-asserted-by": "publisher", "first-page": "65", "journal-title": "Cell Metab", "key": "633_CR69", "unstructured": "Yu B, Li C, Sun Y, Wang DW. Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes. Cell Metab. 2021;33:65-77.e2.", "volume": "33", "year": "2021" }, { "DOI": "10.1111/jcmm.16431", "author": "S Yuan", "doi-asserted-by": "publisher", "first-page": "3484", "journal-title": "J Cell Mol Med", "key": "633_CR70", "unstructured": "Yuan S, Li H, Chen C, Wang F, Wang DW. Association of glycosylated haemoglobin HbA1c levels with outcome in patients with COVID-19: a retrospective study. J Cell Mol Med. 2021;25:3484–97.", "volume": "25", "year": "2021" }, { "DOI": "10.12998/wjcc.v8.i22.5576", "author": "J-H Zhou", "doi-asserted-by": "publisher", "first-page": "5576", "journal-title": "World J Clin Cases", "key": "633_CR71", "unstructured": "Zhou J-H, Wu B, Wang W-X, Lei F, Cheng X, Qin J-J, et al. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases. 2020;8:5576–88.", "volume": "8", "year": "2020" }, { "DOI": "10.3389/fendo.2020.600439", "author": "AB Crouse", "doi-asserted-by": "publisher", "first-page": "600439", "journal-title": "Front Endocrinol.", "key": "633_CR72", "unstructured": "Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol. 2021;11:600439.", "volume": "11", "year": "2021" }, { "DOI": "10.1111/bcp.15258", "author": "A Ganesh", "doi-asserted-by": "publisher", "first-page": "2642", "journal-title": "Br J Clin Pharmacol", "key": "633_CR73", "unstructured": "Ganesh A, Randall MD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:2642–56.", "volume": "88", "year": "2022" }, { "DOI": "10.1002/jmv.26498", "author": "CS Kow", "doi-asserted-by": "publisher", "first-page": "695", "issue": "02", "journal-title": "J Med Virol", "key": "633_CR74", "unstructured": "Kow CS, Hasan SS. 2020 Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. J Med Virol. 2021;93(02):695–7.", "volume": "93", "year": "2021" }, { "DOI": "10.1016/j.obmed.2020.100290", "author": "TI Hariyanto", "doi-asserted-by": "publisher", "first-page": "100290", "journal-title": "Obes Med", "key": "633_CR75", "unstructured": "Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290.", "volume": "19", "year": "2020" }, { "key": "633_CR76", "unstructured": "Obiri-Yeboah D, Bena J, Alwakeel M, Buehler L, Makin V, Zhou K, et al.Association of metformin, dipeptidyl dipeptidase-4 inhibitors, and insulin with COVID-19-related hospital outcomes in patients with type 2 diabetes. Endocr Pract. 2023 Jun 8:S1530–891X(23)00429–9." }, { "DOI": "10.1056/NEJMoa2201662", "author": "CT Bramante", "doi-asserted-by": "publisher", "first-page": "599", "issue": "7", "journal-title": "N Engl J Med", "key": "633_CR77", "unstructured": "Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for covid-19. N Engl J Med. 2022;387(7):599–610.", "volume": "387", "year": "2022" }, { "DOI": "10.1016/j.diabres.2020.108183", "author": "S Sharma", "doi-asserted-by": "publisher", "first-page": "108183", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR78", "unstructured": "Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract. 2020;164:108183.", "volume": "164", "year": "2020" }, { "DOI": "10.3389/fimmu.2020.02056", "author": "X Chen", "doi-asserted-by": "publisher", "first-page": "2056", "journal-title": "Front Immunol", "key": "633_CR79", "unstructured": "Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and antiviral activity of metformin and its potential implications in treating coronavirus disease 2019 and lung injury. Front Immunol. 2020;11:2056.", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.metabol.2022.155196", "author": "NN Nguyen", "doi-asserted-by": "publisher", "first-page": "155196", "journal-title": "Metabolism", "key": "633_CR80", "unstructured": "Nguyen NN, Ho DS, Nguyen HS, Ho DKN, Li H-Y, Lin C-Y, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis. Metabolism. 2022;131:155196.", "volume": "131", "year": "2022" }, { "DOI": "10.1016/j.clinthera.2023.02.007", "author": "A Foresta", "doi-asserted-by": "publisher", "first-page": "e115", "issue": "4", "journal-title": "Clin Ther", "key": "633_CR81", "unstructured": "Foresta A, Ojeda-Fernandez L, Macaluso G, Roncaglioni MC, Tettamanti M, Fortino I, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors and COVID-19 outcomes. Clin Ther. 2023;45(4):e115-26.", "volume": "45", "year": "2023" }, { "DOI": "10.1093/ehjcvp/pvac044", "author": "G Ferrannini", "doi-asserted-by": "publisher", "first-page": "10", "issue": "1", "journal-title": "Eur Heart J Cardiovasc Pharmacother", "key": "633_CR82", "unstructured": "Ferrannini G, Lund LH, Benson L, Rizzo M, Almahmeed W, Rosano GMC, et al. Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis. Eur Heart J Cardiovasc Pharmacother. 2022;9(1):10–7.", "volume": "9", "year": "2022" }, { "DOI": "10.1016/j.diabres.2022.110205", "author": "H Permana", "doi-asserted-by": "publisher", "first-page": "110205", "journal-title": "Diabetes Res Clin Pract", "key": "633_CR83", "unstructured": "Permana H, Audi Yanto T, Ivan HT. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT 2i) may significantly improves Covid-19 outcomes in patients with diabetes: a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2023;195:110205.", "volume": "195", "year": "2023" }, { "DOI": "10.1080/03007995.2022.2027141", "author": "A Alshnbari", "doi-asserted-by": "publisher", "first-page": "357", "issue": "3", "journal-title": "Curr Med Res Opin", "key": "633_CR84", "unstructured": "Alshnbari A, Idris I. Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - Targeting hyperinflammation. Curr Med Res Opin. 2022;38(3):357–64.", "volume": "38", "year": "2022" }, { "DOI": "10.3389/fendo.2022.895458", "author": "Y Chen", "doi-asserted-by": "publisher", "first-page": "895458", "issue": "13", "journal-title": "Front Endocrinol", "key": "633_CR85", "unstructured": "Chen Y, Lv X, Lin S, Arshad M, Dai M. The association between antidiabetic agents and clinical outcomes of COVID-19 patients with diabetes: a Bayesian network meta-analysis. Front Endocrinol. 2022;27(13):895458. https://doi.org/10.3389/fendo.2022.895458.", "volume": "27", "year": "2022" }, { "DOI": "10.3389/fendo.2021.696087", "author": "Y Yang", "doi-asserted-by": "publisher", "first-page": "696087", "journal-title": "Front Endocrinol", "key": "633_CR86", "unstructured": "Yang Y, Cai Z, Zhang J. Insulin treatment may increase adverse outcomes in patients with covid-19 and diabetes: a systematic review and metaanalysis. Front Endocrinol. 2021;12:696087.", "volume": "12", "year": "2021" }, { "author": "T Han", "first-page": "00167", "issue": "21", "journal-title": "Arch Med Res", "key": "633_CR87", "unstructured": "Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, et al. The association between anti-diabetic agents and clinical outcomes of covid-19 in patients with diabetes: a systematic review and meta-analysis. Arch Med Res. 2021;S0188–4409(21):00167–73.", "volume": "S0188–4409", "year": "2021" }, { "DOI": "10.1080/07435800.2021.1967376", "author": "W Wang", "doi-asserted-by": "publisher", "first-page": "32", "issue": "1", "journal-title": "Endocr Res", "key": "633_CR88", "unstructured": "Wang W, Sun Y, Wang S, Sun Y. The relationship between insulin use and increased mortality in patients with COVID-19 and diabetes: a meta-analysis. Endocr Res. 2022;47(1):32–8.", "volume": "47", "year": "2022" }, { "DOI": "10.1007/s00125-021-05458-8", "author": "S Schlesinger", "doi-asserted-by": "publisher", "first-page": "1480", "issue": "7", "journal-title": "Diabetologia", "key": "633_CR89", "unstructured": "Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021;64(7):1480–91.", "volume": "64", "year": "2021" }, { "DOI": "10.3803/EnM.2021.1048", "author": "D Patoulias", "doi-asserted-by": "publisher", "first-page": "904", "issue": "4", "journal-title": "Endocrinol Metab", "key": "633_CR90", "unstructured": "Patoulias D, Doumas M. Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies. Endocrinol Metab. 2021;36(4):904–8.", "volume": "36", "year": "2021" }, { "DOI": "10.3389/fendo.2021.708494", "author": "C Kan", "doi-asserted-by": "publisher", "first-page": "708494", "journal-title": "Front Endocrinol (Lausanne)", "key": "633_CR91", "unstructured": "Kan C, Zhang Y, Han F, Xu Q, Ye T, Hou N, et al. Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:708494.", "volume": "12", "year": "2021" }, { "DOI": "10.2217/fvl-2022-0112", "author": "S Nag", "doi-asserted-by": "publisher", "journal-title": "Future Virol.", "key": "633_CR92", "unstructured": "Nag S, Mandal S, Mukherjee O, Mukherjee S, Kundu R. DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes. Future Virol. 2023. https://doi.org/10.2217/fvl-2022-0112.", "year": "2023" }, { "DOI": "10.1016/j.dsx.2020.06.015", "author": "JM Jagat", "doi-asserted-by": "publisher", "first-page": "829", "issue": "5", "journal-title": "Diabetes Metab Syndr.", "key": "633_CR93", "unstructured": "Jagat JM, Kalyan KG, Subir R. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): boon or bane? Diabetes Metab Syndr. 2020;14(5):829–31.", "volume": "14", "year": "2020" }, { "DOI": "10.1042/BST20200505", "author": "Spencer J Williams", "doi-asserted-by": "publisher", "first-page": "1287", "issue": "3", "journal-title": "Biochem Soc Trans", "key": "633_CR94", "unstructured": "Williams Spencer J, Goddard-Borger Ethan D. α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19. Biochem Soc Trans. 2020;48(3):1287–95.", "volume": "48", "year": "2020" } ], "reference-count": 94, "references-count": 94, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s43441-024-00633-6" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }